Ceftolozane/tazobactam for the treatment of serious P. aeruginosa infections: a multicenter nationwide clinical experience
Pseudomonas aeruginosa is a leading cause of nosocomial infections, which are often severe [1, 2] and difficult to treat because of their increasing resistance to several antibiotics, including carbapenems [3-6]. For such infections, there are limited therapeutic options, and old antibiotics such as colistin, aminoglycosides or fosfomycin are frequently prescribed [7]. Clinical failure [8], emergence of in vivo resistance [9], superinfection, and nephrotoxicity [10, 11] represent the main limitations of the currently available drugs, leading to the search of new treatment options.
Source: International Journal of Antimicrobial Agents - Category: Drugs & Pharmacology Authors: Matteo Bassetti, Nadia Castaldo, Annamaria Cattelan, Cristina Mussini, Elda Righi, Carlo Tascini, Francesco Menichetti, Claudio Maria Mastroianni, Mario Tumbarello, Paolo Grossi, Stefania Artioli, Novella Carrannante, Ludovica Cipriani, Davide Coletto, Al Source Type: research
More News: Drugs & Pharmacology | Men